Kezar Life Sciences, Inc.

DB:2KZ0 Stock Report

Market Cap: €46.6m

Kezar Life Sciences Management

Management criteria checks 2/4

Kezar Life Sciences' CEO is Chris Kirk, appointed in Nov 2023, has a tenure of 1.17 years. total yearly compensation is $2.60M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth €275.55K. The average tenure of the management team and the board of directors is 2.2 years and 7.7 years respectively.

Key information

Chris Kirk

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage9.3%
CEO tenure1.2yrs
CEO ownership0.6%
Management average tenure2.2yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Kirk's remuneration changed compared to Kezar Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$99m

Mar 31 2024n/an/a

-US$101m

Dec 31 2023US$3mUS$242k

-US$102m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$2mUS$468k

-US$68m

Sep 30 2022n/an/a

-US$64m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$58m

Dec 31 2021US$2mUS$443k

-US$55m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$48m

Mar 31 2021n/an/a

-US$45m

Dec 31 2020US$880kUS$426k

-US$42m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$2mUS$410k

-US$35m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$962kUS$365k

-US$23m

Compensation vs Market: Chris's total compensation ($USD2.60M) is above average for companies of similar size in the German market ($USD460.80K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Kirk (52 yo)

1.2yrs

Tenure

US$2,602,155

Compensation

Dr. Christopher J. Kirk, also known as Chris, Ph.D. serves as Member of Scientific Advisory Board at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) He is a Co-Founder of Kezar Life Sciences,...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Kirk
Co-Founder1.2yrsUS$2.60m0.59%
€ 275.5k
John Fowler
Co-Founder & Directorno dataUS$4.83m0.60%
€ 278.6k
Marc Belsky
CFO & Secretary6.8yrsUS$2.01m0.026%
€ 12.0k
Jack Taunton
Co-Founderno datano datano data
Gitanjali Jain
Senior Vice President of Investor Relations & External Affairsno datano datano data
Mark Schiller
Chief Legal Officer5.8yrsno data0.025%
€ 11.5k
Joe Tedrick
Vice President of Human Resourcesless than a yearno datano data
Neel Anand
Senior Vice President of Research & Drug Discovery2.8yrsno datano data
Zung To
Senior Vice President of Clinical Development1.7yrsno datano data
Pattie Chiang
Senior VP & Corporate Controllerno datano datano data

2.2yrs

Average Tenure

52yo

Average Age

Experienced Management: 2KZ0's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Kirk
Co-Founder9.9yrsUS$2.60m0.59%
€ 275.5k
John Fowler
Co-Founder & Director9.9yrsUS$4.83m0.60%
€ 278.6k
Michael Kauffman
Independent Director8.1yrsUS$155.34k0.087%
€ 40.7k
Franklin Berger
Independent Director9yrsUS$141.22k1.22%
€ 569.0k
Graham Cooper
Independent Chairman7.3yrsUS$194.56k0%
€ 0
Elizabeth Ijeoma Garner
Independent Director5.1yrsUS$149.45k0%
€ 0
Courtney Wallace
Independent Director3.1yrsUS$164.59k0%
€ 0
Micki Klearman
Independent Director3.6yrsUS$161.58k0%
€ 0

7.7yrs

Average Tenure

54yo

Average Age

Experienced Board: 2KZ0's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 09:55
End of Day Share Price 2024/10/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kezar Life Sciences, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC
Catherine NovackJonesTrading Institutional Services, LLC